Aurobindo Pharma receives 10 observations for Unit IX
The company had responded to the agency and carried out the required corrective actions.
The company had responded to the agency and carried out the required corrective actions.
The product is expected to be launched by Q4 FY23.
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
The company is focussed on increasing the capacity utilizations while controlling costs
The company sees the business reaching $100mn
Subscribe To Our Newsletter & Stay Updated